# Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

> **NCT05691361** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ADARx Pharmaceuticals, Inc.** · enrollment: 53 (estimated)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** ADX-324
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05691361
- **Lead sponsor:** ADARx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05691361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05691361, "Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05691361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*